Literature DB >> 22343518

Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles.

Xia Cao1, Min Fu, Liang Wang, Hongfei Liu, Wenwen Deng, Rui Qu, Weiyan Su, Yawei Wei, Ximing Xu, Jiangnan Yu.   

Abstract

The purpose of this study was to develop porous silica nanoparticles (PSNs) as a carrier to improve oral bioavailability of poorly water-soluble drugs, using silymarin as a model. PSNs were synthesized by reverse microemulsion and ultrasonic corrosion methods. A 3-day release formulation consisting of a silymarin solid dispersion, a hydrophilic gel matrix and silymarin-loaded PSNs was prepared. In vitro release studies indicated that both the silymarin-loaded PSNs and the 3-day release formulation showed a typical sustained-release pattern over a long period, about 72 h. The in vivo studies revealed that the 3-day release formulation gave a significantly higher plasma concentration and larger area under the concentration-time curves than commercial tablets when orally administered to beagle dogs. This implies that the prepared 3-day release formulation significantly enhanced the oral bioavailability of silymarin, suggesting that PSNs can be used as promising drug carriers for oral sustained release systems. Thus providing a technically feasible approach for improving the oral bioavailability and long-term efficacy of poorly soluble drugs.
Copyright © 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343518     DOI: 10.1016/j.actbio.2012.02.011

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  8 in total

1.  Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health.

Authors:  Iris R Bell; Gary E Schwartz; Nancy N Boyer; Mary Koithan; Audrey J Brooks
Journal:  Eur J Integr Med       Date:  2013-04-01       Impact factor: 1.314

2.  Ergosterol-loaded poly(lactide-co-glycolide) nanoparticles with enhanced in vitro antitumor activity and oral bioavailability.

Authors:  Hui-Yun Zhang; Caleb Kesse Firempong; Yuan-Wen Wang; Wen-Qian Xu; Miao-Miao Wang; Xia Cao; Yuan Zhu; Shan-Shan Tong; Jiang-Nan Yu; Xi-Ming Xu
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

3.  Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfide bond bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy.

Authors:  Huiyun Zhang; Wenqian Xu; Emmanuel Omari-Siaw; Yingkun Liu; Baoding Chen; Deyu Chen; Jiangnan Yu; Ximing Xu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 4.  Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art.

Authors:  Alfonso Di Costanzo; Ruggero Angelico
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

5.  Synthesis of Pore-Size-Tunable Mesoporous Silica Nanoparticles by Simultaneous Sol-Gel and Radical Polymerization to Enhance Silibinin Dissolution.

Authors:  Mina Shafiee; Samirasadat Abolmaali; Mozhgan Abedanzadeh; Mehdi Abedi; Alimohammad Tamaddon
Journal:  Iran J Med Sci       Date:  2021-11

6.  Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: preparation by supercritical fluid technology and evaluation in vitro and in vivo.

Authors:  Gang Yang; Yaping Zhao; Yongtai Zhang; Beilei Dang; Ying Liu; Nianping Feng
Journal:  Int J Nanomedicine       Date:  2015-10-22

7.  A New Type of Liquid Silymarin Proliposome Containing Bile Salts: Its Preparation and Improved Hepatoprotective Effects.

Authors:  Mei Wang; Tingting Xie; Zhanying Chang; Ling Wang; Xiangyun Xie; Yaohong Kou; Hongxia Xu; Xiaoli Gao
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

Review 8.  Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.

Authors:  Hammad Ullah; Haroon Khan
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.